PIVKA‐II revealed the best predictive performance compared to AFP and AFP‐L3, in studies which evaluated HCC patients and patients with chronic hepatitis C15 or patients with benign liver lesions, liver metastases, and other gastrointestinal malignancies.16 Here, AFP is linked to chronic hepatitis.